Vaxil Bio Ltd's stock has taken a significant hit, shedding over 5% in a single day.
Vaxil Bio Ltd (VXL.V) saw its stock price drop 5.88% today, closing at CA$0.16. This decline is concerning, especially since the company has received limited public attention in recent months.
Advertisement
Vaxil Bio Ltd
VXL.V
VXL.V
Vaxil Bio Ltd
WealthAwesomeMarket cap
$677,283
P/E
1.1x
52W high
$0.29
52W low
$0.13
1W change
-2.86%
Beta
-0.87
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VXL's historical volatility
30-Day Vol
74.6%
Annualized
90-Day Vol
108.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.14
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.16 | C$0.12 – C$0.21 |
| 60 trading days | C$0.15 | C$0.10 – C$0.22 |
| 90 trading days | C$0.14 | C$0.09 – C$0.22 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Vaxil Bio Ltd's recent performance raises concerns about its financial stability and market perception.
Vaxil Bio Ltd's stock drops 5.88% today
The company's market cap now stands at CA$677,283, reflecting a challenging environment for small-cap stocks.
Bull case
There might be some potential for Vaxil, as the company reported a net income for the full year 2025, indicating possible future growth.
Bear case
However, today's significant stock price drop highlights ongoing skepticism among investors, especially in light of the recent net losses reported in Q1 2026 and the company's limited visibility in the market.
Advertisement
Recent Performance and Market Sentiment
Vaxil Bio Ltd's stock price has fallen sharply today, reflecting broader concerns among investors about its financial outlook. The company recently reported a net loss of CAD 0.107 million for Q1 2026, a stark contrast to its performance last year. This decline in earnings has likely fueled negative sentiment surrounding the stock. Investors may want to keep a close eye on the company's upcoming announcements.
Financial Overview
With a current market cap of CA$677,283 and a P/E ratio of 1.1333, Vaxil Bio Ltd remains a small player in the biotechnology sector. While the recent earnings report indicated a net income of CAD 0.522 million for the full year 2025, the latest quarterly results have raised concerns. Investors should consider these financial metrics alongside the stock's recent performance and market conditions. For more insights, check out our detailed analysis on Vaxil Bio Ltd.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
